Enhanced External Counterpulsation

Last updated: May 17, 2011
Sponsor: Far Eastern Memorial Hospital
Overall Status: Completed

Phase

N/A

Condition

Coronary Artery Disease

Hypercholesterolemia

Atherosclerosis

Treatment

N/A

Clinical Study ID

NCT01355315
95005
FEMH-95-C-039
  • All Genders

Study Summary

Enhanced external counterpulsation (EECP) is a noninvasive circulatory assist device that has been as a treatment option for refractory angina in left ventricular (LV) dysfunction. Recently, its potential role in heart failure management has been shown. However, although the concept of EECP was introduced almost four decades ago, and despite growing evidence supporting the clinical benefit and safety of this therapeutic modality, little is firmly established regarding the mechanisms responsible for the benefit of EECP include improvement in endothelial function, promotion of coronary collateralization, enhancement of ventricular function, and peripheral effects. Therefore, the major aim of this study is to provide an alternative treatment, EECP, for those unsuitable for standard procedures, especially for patients whose heart failure was caused by repeated myocardial infarction, called ischemic cardiomyopathy (ICMP), and to evaluate the clinical outcome and the endothelial function before and after 35 hours of EECP treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • The inclusion criteria is left ventricular ejection fraction (LVEF) less than 40% bymeans of left ventricular angiography and symptomatic mild-to-moderate heart failure (New York Heart Association [NYHA] functional class II-III). The patient was includedif there is no suitable target for either percutaneous coronary intervention orsurgical bypass grafting.

Exclusion

Exclusion Criteria:

  • IF he/she has moderate or severe aortic regurgitation (AR), history of deep veinthrombosis, or significant arrhythmia.

Study Design

Total Participants: 19
Study Start date:
April 01, 2006
Estimated Completion Date: